Sitafloxacin hydrate Catalog No.:M8991-10 it potently inhibits ABL-T315I

it potently inhibits ABL-T315I

Treatment of AML cell lines (MV4-11 and THP-1) and primary blasts with HLCL-61 also results in a decrease of cell viability

1 In clinical trials

InChiKey: ZHMWOVGZCINIHW-FTYOSCRSSA-N

TG100-115 was also assayed against a 133 protein kinase panel

Sitafloxacin hydrate Catalog No.:M8991-10 it potently inhibits ABL-T315ISitafloxacin is a new generation, broad spectrum oral fluoroquinolone that is very active against many Gram positive, Gram negative and anaerobic clinical isolates, including strains resistant to other fluoroquinolones, was recently approved in Japan for the treatment of respiratory and urinary tract infections. Sitafloxacin is active against methicillin resistant staphylococci, Streptococcus pneumoniae and other streptococci with reduced